Epitomics Launches New Line of Rabbit Monoclonal Antibodies for the Anatomic Pathology Market
BURLINGAME, Calif., Aug. 9 /PRNewswire/ — Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone(TM) Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States, these products are manufactured under FDA’s Quality System Regulation (21 CFR, Part 820). Each product is either labeled “In Vitro Diagnostics (IVD)” or “Analyte Specific Reagents (ASR)” based on its intended application.
“By launching diagnostic IHC products into the rapidly growing pathology market, we have achieved another major milestone for Epitomics rabbit monoclonal antibody (RabMAbÃ‚®) technology” said Dr. Guo-Liang Yu, President and CEO of Epitomics, Inc. “Precision detection of biomarkers in cancers is critical for cancer treatment. RabMAbs have been proven to be the “best in class” immunologic probes for detecting cancer and other disease targets in pathologic tissues. We have developed a broad portfolio of RabMAbs for pathologists to use to generate meaningful information to help diagnose and aid physicians to design better treatment strategies. We are proud that our technology will provide great benefits to the diagnosis and treatment of cancer”.
About RabMAbÃ‚® technology
Compared to currently available mAb technology on the market, such as mouse hybridomas, Epitomics’ technology can generate antibodies more efficiently and can offer superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle.
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAbÃ‚® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People’s Republic of China. Visit www.epitomics.com.
SOURCE Epitomics, Inc.